On Nov @ , @ , all patients assigned to fingolimod @ mg were switched to the @ mg dose in a blinded manner after a review of data from other phase @ trials and recommendation from the data and safety monitoring board , but were analysed as being in the @ mg group in the primary outcome analysis .